JAHA:HIV患者血清PCSK9水平与冠脉内皮功能呈负相关

2018-09-30 MedSci MedSci原创

HIV阳性病人患冠心病的风险会增高,但具体机制尚未阐明。本研究纳入分析了48例接受抗病毒治疗的无冠心病的HIV阳性患者,以及15例年龄和低密度脂蛋白胆固醇匹配的正常对照,对其进行磁共振检查以评估冠脉内皮功能,并抽取血样检测血清PCSK9水平和血管标志物水平。分析结果显示,HIV阳性患者的血清PCSK9水平高出正常对照65%(P<0.0001),且HIV患者的冠脉内皮功能明显降低,并与血清PC

HIV阳性病人患冠心病的风险会增高,但具体机制尚未阐明。

本研究纳入分析了48例接受抗病毒治疗的无冠心病的HIV阳性患者,以及15例年龄和低密度脂蛋白胆固醇匹配的正常对照,对其进行磁共振检查以评估冠脉内皮功能,并抽取血样检测血清PCSK9水平和血管标志物水平。分析结果显示,HIV阳性患者的血清PCSK9水平高出正常对照65%(P<0.0001),且HIV患者的冠脉内皮功能明显降低,并与血清PCSK9水平呈负相关。另外,内皮损伤的标志物在HIV阳性患者中也明显更高。

研究结果显示,血清PCSK9水平在HIV阳性患者中明显增高,且与冠脉内皮功能的降低相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003365, encodeId=018c2003365c4, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Apr 05 08:57:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Feb 07 17:57:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685612, encodeId=4dec16856128e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Jun 23 22:57:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267939, encodeId=de17126e9391a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450045, encodeId=909d14500454b, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573239, encodeId=08be15e323955, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003365, encodeId=018c2003365c4, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Apr 05 08:57:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Feb 07 17:57:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685612, encodeId=4dec16856128e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Jun 23 22:57:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267939, encodeId=de17126e9391a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450045, encodeId=909d14500454b, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573239, encodeId=08be15e323955, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=)]
    2019-02-07 FukaiBao
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003365, encodeId=018c2003365c4, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Apr 05 08:57:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Feb 07 17:57:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685612, encodeId=4dec16856128e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Jun 23 22:57:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267939, encodeId=de17126e9391a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450045, encodeId=909d14500454b, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573239, encodeId=08be15e323955, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=)]
    2019-06-23 Tamikia
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003365, encodeId=018c2003365c4, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Apr 05 08:57:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Feb 07 17:57:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685612, encodeId=4dec16856128e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Jun 23 22:57:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267939, encodeId=de17126e9391a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450045, encodeId=909d14500454b, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573239, encodeId=08be15e323955, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=)]
    2018-10-02 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=2003365, encodeId=018c2003365c4, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Apr 05 08:57:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Feb 07 17:57:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685612, encodeId=4dec16856128e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Jun 23 22:57:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267939, encodeId=de17126e9391a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450045, encodeId=909d14500454b, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573239, encodeId=08be15e323955, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2003365, encodeId=018c2003365c4, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Apr 05 08:57:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777268, encodeId=3c631e772685b, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Thu Feb 07 17:57:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685612, encodeId=4dec16856128e, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Sun Jun 23 22:57:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267939, encodeId=de17126e9391a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450045, encodeId=909d14500454b, content=<a href='/topic/show?id=85eb304409c' target=_blank style='color:#2F92EE;'>#内皮功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30440, encryptionId=85eb304409c, topicName=内皮功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41d5536295, createdName=zhangxingru, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573239, encodeId=08be15e323955, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Tue Oct 02 11:57:00 CST 2018, time=2018-10-02, status=1, ipAttribution=)]
    2018-10-02 hmwwww

相关资讯

JAHA:急性心梗伴肝硬化患者的β受体阻滞剂该如何选择?

目前,β1选择性抑制剂或非选择性β抑制剂对于肝硬化伴急性心梗的患者是否有效尚不清楚。本研究纳入了台湾NHIRD数据库中的患者,并比较了服用β1选择性抑制剂治疗和非选择性β抑制剂患者的预后,主要终点事件是1年和2年的心血管事件、肝脏不良事件和全因死亡率。最终共纳入了203595名急性心梗患者,其中6355名伴有肝硬化。经过排除标准后,共分析了1769名患者(655名接受β受体阻滞剂治疗,1114名没

JAHA:前列腺素受体2在受损心脏修复中起重要作用

前列腺素E2是公认的免疫调节因子,它在组织受损后释放,并参与调控巨噬细胞的活性,然而前列腺素受体2(EP2)调节的巨噬细胞在心脏缺血后的作用尚不清楚。本研究的目的旨在探究EP2在受损心脏中的作用。本研究利用EP2转基因小鼠模型,发现EP2敲除小鼠的心脏在受损后心功能会更差,并且EP2的缺失会改变促炎反应,导致巨噬细胞聚集于受损心肌的缺陷。转录组分析结果显示红系分化调节蛋白1(Erdr1)在EP2敲

JAHA:心血管危险因素对女性冠心病和卒中的影响

心血管危险因素对心血管疾病的各种表现有不同的影响,但到目前为止,直接进行比较较少见,且主要在男性中比较。本研究纳入比较了1731名心血管疾病的女性与1914名正常的女性,发现24大危险因素(包括各种载脂蛋白、血红蛋白A1C、高灵敏度C反应蛋白、N末端脑钠肽和组织纤溶酶原激活物抗原)的作用方向在冠心病(CHD)和缺血性卒中中是一致的,但在CHD中相关性更强。当比较出血性脑卒中与缺血性脑卒中的疗效时,

JAHA:他汀类药物可改善腹主动脉瘤患者预后

目前,腹主动脉瘤(AAA)没有特效的药物治疗,尽管有研究显示他汀类药物对AAA有益处。本荟萃分析的目的旨在评估他汀类药物对AAA的生长、破裂和30天死亡率的影响。本次荟萃分析纳入分析了911篇临床文章,包括1个病例对照研究和21个队列研究,共计80428例患者。分析结果显示,他汀类药物的使用与AAA生长率减少0.82 mm/y呈相关性(95% Cl 0.33- 1.32,P=0.001, I2=8

JACC:血栓抽吸不能改善高血栓风险STEMI患者预后

常规的血栓抽吸对接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者来说并不会改善预后,但对有高血栓风险的该类患者来说是否有益尚不清楚。本研究的目的旨在评估血栓抽吸对伴高血栓风险的STEMI患者是否有益。本研究纳入的是TOTAL临床研究中的STEMI患者,主要终点事件是心源性死亡、心梗、心源性休克和心衰。分析结果显示,1年主要终点事件在接受血栓抽吸的高血栓风险STEMI患者和不接受抽

JACC:二尖瓣环分离心律失常综合征

二尖瓣环分离(MAD)会引起二尖瓣脱垂(MVP)和心源性猝死。本研究的目的旨在评估MAD患者的临床特征、二尖瓣形态、MVP情况及室性心律失常情况。本研究最终纳入了116名MAD患者(平均年龄49±15岁,女性占60%)。心悸是最常见的临床症状(71%),严重的心律不齐占14例(12%)。伴心律不齐的MAD患者年龄更小(p = 0.001),射血分数更低(51 ± 5% vs. 57 ± 7%; p